Yngvild K Olsen
Overview
Explore the profile of Yngvild K Olsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
224
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Monico L, Mitchell S, Gryczynski J, Schwartz R, OGrady K, Olsen Y, et al.
J Subst Abuse Treat
. 2015 May;
57:57-62.
PMID: 25980599
Buprenorphine availability continues to expand as an effective treatment for opioid dependence, but increases in availability have also been accompanied by increases in non-prescribed use of the medication. Utilizing data...
2.
Mitchell S, Gryczynski J, Schwartz R, Myers C, OGrady K, Olsen Y, et al.
J Psychoactive Drugs
. 2015 May;
47(2):149-57.
PMID: 25950595
Studies of substance abuse treatment outcomes that give priority to cessation of all drug use may obscure other tangible benefits of treatment that are important to patients. The aim of...
3.
Mitchell S, Gryczynski J, Kelly S, OGrady K, Jaffe J, Olsen Y, et al.
J Drug Issues
. 2014 Nov;
44(1):69-82.
PMID: 25364037
This secondary analysis compared outcomes of African-American adults newly-admitted to buprenorphine treatment who were on parole and probation to patients who were not under criminal justice supervision. Buprenorphine patients (N=300)...
4.
Gryczynski J, Mitchell S, Jaffe J, OGrady K, Olsen Y, Schwartz R
J Subst Abuse Treat
. 2013 Nov;
46(3):356-61.
PMID: 24238714
Many opioid-dependent patients leave treatment prematurely. This study is a planned secondary analysis from a randomized trial of counseling for African Americans (N=297) entering buprenorphine treatment at one of two...
5.
Schwartz R, Gryczynski J, OGrady K, Sharfstein J, Warren G, Olsen Y, et al.
Am J Public Health
. 2013 Jun;
103(8):e2-3.
PMID: 23763406
No abstract available.
6.
Gryczynski J, Jaffe J, Schwartz R, Dusek K, Gugsa N, Monroe C, et al.
Am J Addict
. 2013 Apr;
22(3):285-91.
PMID: 23617873
Background: Recent policy initiatives in Baltimore City, MD significantly reduced access disparities between methadone and buprenorphine in the publicly funded treatment sector. Objectives: This study examines reasons for choosing buprenorphine...
7.
Gryczynski J, Mitchell S, Jaffe J, Kelly S, Myers C, OGrady K, et al.
J Subst Abuse Treat
. 2013 Apr;
45(3):287-92.
PMID: 23566446
Methadone has been the most commonly used pharmacotherapy for the treatment of opioid dependence in U.S. public sector treatment, but availability of buprenorphine as an alternative medication continues to increase....
8.
Mitchell S, Gryczynski J, Schwartz R, OGrady K, Olsen Y, Jaffe J
Drug Alcohol Depend
. 2012 Sep;
128(3):222-9.
PMID: 22999817
Background: Buprenorphine is increasingly being used in community-based treatment programs, but little is known about the optimal level of psychosocial counseling in these settings. The aim of this study was...
9.
Mitchell S, Kelly S, Gryczynski J, Myers C, Jaffe J, OGrady K, et al.
Drug Alcohol Depend
. 2011 Oct;
122(1-2):55-60.
PMID: 21962726
Background: To expand its public-sector treatment capacity, Baltimore City made buprenorphine treatment accessible to low-income, largely African American residents. This study compares the characteristics of patients entering methadone treatment vs....